Document is current
Any future updates will be listed below
-
Authors
Wan, Melissa https://orcid.org/0000-0002-0001-0677
Simonin, Elisabeth M https://orcid.org/0000-0001-9195-5061
Johnson, Mary Margaret
Zhang, Xinyue https://orcid.org/0000-0001-6093-6335
Lin, Xiangping https://orcid.org/0000-0001-6045-4459
Gao, Peng
Patel, Chirag J
Yousuf, Aroub https://orcid.org/0000-0002-7894-324X
Snyder, Michael P https://orcid.org/0000-0003-0784-7987
Hong, Xiumei
Wang, Xiaobin
Sampath, Vanitha
Nadeau, Kari C https://orcid.org/0000-0002-2146-2955
-
Funding
Funding for this research was provided by:
HHS | NIH | National Institute of Allergy and Infectious Diseases (R21AI1492771,R21EB030643,U01AI140498,U01 AI147462,R01AI140134,UM1AI109565,UM2AI130836,P01AI15)
HHS | NIH | National Heart, Lung, and Blood Institute (P01 HL152953,R01 HL141851)
HHS | NIH | National Institute of Environmental Health Sciences (R21ES03304901,R01ES032253)
- License Information
-
More Information
Article History
Received: 23 June 2024
Revised: 6 December 2024
Accepted: 24 December 2024
First Online: 27 January 2025
Disclosure and competing interests statement
: XZ is a cofounder of Exposomics, Inc. MPS is a cofounder and scientific advisor of Crosshair Therapeutics, Exposomics, Filtricine, Fodsel, iollo, InVu Health, January AI, Marble Therapeutics, Mirvie, Next Thought AI, Orange Street Ventures, Personalis, Protos Biologics, Qbio, RTHM, SensOmics. MPS is a scientific advisor of Abbratech, Applied Cognition, Enovone, Jupiter Therapeutics, M3 Helium, Mitrix, Neuvivo, Onza, Sigil Biosciences, TranscribeGlass, WndrHLTH, Yuvan Research. MPS is a cofounder of NiMo Therapeutics. MPS is an investor and scientific advisor of R42 and Swaza. MPS is an investor in Repair Biotechnologies. All other authors declare no conflict of interest.
